Drug Trial Radar · NCT06265220
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
51
Planned (sponsor's estimate)
Start
Apr 3, 2024
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Artiva Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies. This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approaches, or other forms of refractory systemic lupus erythematosus. The primary objective is to assess the safety, tolerability and preliminary activity of AB-101 plus a B-cell depleting mAb (e.g., rituximab, obinutuzumab) after cyclophosphamide and fludarabine in adult subjects with relapsed/refractory lupus nephritis Class III or IV, with or without the presence of Class V, or other forms of refractory systemic lupus erythematosus. Patients will be assigned to receive either AB-101 alone as monotherapy or in combination with a B-cell depleting mAb (e.g., rituximab, obinutuzumab). All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and response status. Patients may receive up to 2 cycles of treatment spaced 24 weeks apart.
Conditions
- Lupus Nephritis - WHO Class III
- Lupus Nephritis - WHO Class IV
- Refractory Systemic Lupus Erythematosus
- SLE
Interventions
AB-101Drug
NK Cell Therapy
CyclophosphamideDrug
Lymphodepleting chemotherapy
FludarabineDrug
Lymphodepleting chemotherapy
RituximabDrug
Anti-CD20 antibody therapy
ObinutuzumabDrug
Anti-CD20 antibody therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events and Serious Adverse EventsTime frame: From the time of consent through 104 weeks after initiation of study treatment
- AB-101 Clinical ActivityTime frame: From the time of first dose through 104 weeks after initiation of study treatment
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Artiva Investigational Site Birmingham
Birmingham, Alabama
Artiva Investigational Site Tucson
Tucson, Arizona
Artiva Investigational Site San Diego
San Diego, California
Artiva Investigational Site Aventura
Aventura, Florida
Artiva Investigational Site Plantation
Plantation, Florida
Artiva Investigational Site Iowa
Iowa City, Iowa
Artiva Investigational Site Charlotte
Charlotte, North Carolina
Artiva Investigational Site Mesquite
Mesquite, Texas
Artiva Investigational Site Woodlands
The Woodlands, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.